PCSK9 inhibitors have been shown to dramatically reduce LDL-C [39] to levels well below those seen with other lipid lowering therapies.39 In addition, our Pcsk9 null mouse model demonstrated reduced AAA growth following elastase infusion in the absence of a hyperlipidemic background, although small statistical differences in lipid fractions were observed between mice strata. This evidence concerns the gene PCSK9 and triple-A syndrome.